3,5-Bis(arylidene)-4-piperidones as potential dengue protease inhibitors.
Acta Pharm Sin B
; 7(4): 479-484, 2017 Jul.
Article
en En
| MEDLINE
| ID: mdl-28752033
ABSTRACT
Dengue is a severe mosquito-borne viral infection causing half a million deaths annually. Dengue virus NS2B/NS3 protease is a validated target for anti-dengue drug design. A series of hitherto unreported 3,5-bis(arylidene)-4-piperidones analogues 4a-4j were synthesized and screened in silico against DENV2 NS2B/NS3 protease to elucidate their binding mechanism and orientation around the active sites. Results were validated through an in vitro DENV2 NS2B/NS3 protease assay using a fluorogenic Boc-Gly-Arg-Arg-AMC substrate. Nitro derivatives of 3,5-bis(arylidene)-4-piperidones (4e and 4j) emerged as promising lead molecules for novel protease inhibitors with an IC50 of 15.22 and 16.23 µmol/L, respectively, compared to the standard, panduratin A, having IC50 of 57.28 µmol/L.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Acta Pharm Sin B
Año:
2017
Tipo del documento:
Article
País de afiliación:
Malasia